Repotrectinib: ROS1 & NTRK Inhibitor for Cancer
Repotrectinib is a modern, next-generation anti-cancer medication designed to treat certain types of lung cancer and other solid tumors. It belongs to a class of drugs called ROS1 and NTRK inhibitors — it targets specific proteins that, when genetically altered, drive tumor growth.
The key advantage of repotrectinib is that it works even when the tumor has become resistant to other similar drugs (such as crizotinib or entrectinib). It also penetrates the brain effectively, which is important for patients with brain metastases. On Unifarm, you can find generic versions of medications (such as Augtyro) containing this active ingredient.
Indications
- ROS1-Positive Lung Cancer: Treatment of adults with advanced (metastatic) non-small cell lung cancer (NSCLC) where genetic testing has confirmed a ROS1 gene rearrangement. Can be used as a first treatment or after other therapies have stopped working.
- Tumors with NTRK Gene Rearrangement: Treatment of adults with solid tumors of various types where NTRK gene fusions have been identified, and the disease has progressed after prior treatment or when no suitable alternatives exist.
Dosage and administration
Available as capsules taken by mouth.
How to take it:
- Standard dose: 160 mg once daily for the first 14 days, then increased to 160 mg twice daily.
- How to take: Swallow capsules whole with water. Can be taken with or without food.
- If side effects occur: Your doctor may pause treatment or reduce the dose to 120 mg or 80 mg.
Do not open or crush the capsules. If you miss a dose or vomit after taking it, do not take an extra dose — take the next one as scheduled. Your doctor will order regular blood tests and monitor your condition throughout treatment.
